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Abstract
Background:  Acute hyperglycaemia is an independent cardiovascular risk factor in Type 2
diabetes which may be mediated through increased oxidative damage to plasma low density
lipoprotein, and in vitro, high glucose concentrations promote proatherogenic adhesion molecule
expression and matrix metalloproteinase expression.
Methods: We examined these atherogenic risk markers in 21 subjects with Type 2 diabetes and
20 controls during an oral 75 g glucose tolerance test. Plasma soluble adhesion molecule
concentrations [E-selectin, VCAM-1 and ICAM-1], plasma matrix metalloproteinases [MMP-3 and
9] and plasma LDL oxidisability were measured at 30 minute intervals.
Results: In the diabetes group, the concentrations of all plasma soluble adhesion molecules fell
promptly [all p < 0.0001] related principally to glycaemic excursions, but such changes also
occurred in the control group. Plasma MMP-3 and -9 concentrations were lower [p < 0.05], and
LDL oxidisability greater [p < 0.01] in the diabetes group but did not change in either group. There
was a direct relationship between plasma MMP-9 and s ICAM-1 in the controls [r = 0.62; p = 0.006]
perhaps suggesting a functional relationship between s ICAM-1 shedding and MMP-9.
Conclusions:  A glucose load leads to a rapid fall in plasma soluble adhesion molecule
concentrations in Type 2 diabetes and controls, perhaps reflecting reduced generation of soluble
from membrane forms during enhanced leukocyte – endothelial adhesion or increased hepatic
clearance, without changes in plasma matrix metalloproteinase concentrations or low density
lipoprotein oxidisability. These in vivo findings are in contrast with in vitro data.
Introduction
Epidemiological and prospective studies have shown a
consistent direct relationship between blood glucose lev-
els and cardiovascular morbidity and mortality [1] in Type
2 diabetes, but some data suggest acute or post-prandial
hyperglycaemia may be an independent predictor of
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cardiovascular morbidity in these patients and in people
without diabetes [2,3]. Surrogates for macro vascular dis-
ease such as carotid intimal – medial thickness are more
closely related to acute rather chronic hyperglycaemia [4]
and much of the controversy over the recent diagnostic
classification of diabetes was based on the predictive
power of post glucose load hyperglycaemia as a marker for
increased vascular risk [5], which could be mediated by
acute oxidative damage to lipoproteins, proteins and
DNA [6]
Oxidatively modified plasma low density lipoproteins
and elevated glucose concentrations promote the expres-
sion of adhesion molecules on vascular endothelial cells
in vitro [7,8], through a mechanism sensitive to oxidative
balance [8], and soluble forms of some of these adhesion
molecules are a marker of increased macrovascular risk in
people with and without diabetes [9] although there is
uncertainty if they contribute directly to this risk. A further
unexamined link between acute hyperglycaemia and mac-
rovascular disease in Type 2 diabetes is the effect of acute
hyperglycaemia on matrix metalloproteinase [MMP]
expression by cells involved in the atherogenic process.
The MMP system has a role in maintaining the stability of
coronary atheromatous plaque [10], and in vitro some
cellular MMP message and product are actively promoted
by high glucose concentrations and oxidatively damaged
lipoproteins [11], and elevated plasma MMP concentra-
tions may be a feature of coronary atherosclerosis, carotid
plaque instability and a range of inflammatory and malig-
nant processes [12-14]. Finally, acute hyperglycaemia may
be associated with proatherogenic modifications to
plasma lipoproteins [15,16]
We hypothesised that acute glycaemic excursions in sub-
jects with or without Type 2 diabetes would promote LDL
oxidative susceptibility, increase the cell membrane shed-
ding and plasma concentrations of soluble forms of key
adhesion molecules, and promote increased plasma con-
centrations of MMP.
Materials and Methods
Patient selection
After local Ethical Committee approval and written
informed consent, we studied 21 patients with Type 2 dia-
betes and 20 controls. All were non-smokers between 40
and 65 years old, and patients were considered to have
Type 2 diabetes if they had been diagnosed after the age of
40 years, with no history of ketosis and with stable glycae-
mic control on diet or oral hypoglycaemics. Patients with
treated hypertension, with clinical evidence or history of
coronary artery disease, or receiving hormone replace-
ment therapy or insulin were excluded. Patients with
microalbuminuria [defined as an elevated urine albumin:
creatinine ratio] or macroproteinuria [defined as albustix
positive proteinuria] were also excluded. Seven of the 21
patients had background retinopathy, by definition none
had microalbuminuria and 6 were diet controlled alone.
All controls had a fasting plasma glucose below 6.1
mmol/l and had no significant past medical history of
hypertension or cardiovascular disease. Baseline data are
shown in Table 1.
Table 1: Baseline data on 21 subjects with Type 2 diabetes and 20 controls without diabetes.
Type 2 diabetes Controls p
Number 21 20
Age [yrs] 57.1 [6.3] 59.0 [9.9] ns
Known Diabetes duration [yrs] 5.7 [7.1] -
M:F 10:11 11:9 ns
Body Mass Index [kg/m2] 30.1 [4.8] 26.7 [3.8] ns
Waist – hip ratio 0.91 [0.09] 0.86 [0.08] ns
Diabetes treatment -
Diet 6
Sulphonylurea 6
Metformin 5
Combination 4
HbA1c [%] 7.3 [1.3] 5.1 [0.3] 0.0001
Total cholesterol [mmol/l] 5.8 [0.7] 5.8 [0.9] ns
LDL cholesterol [mmol/l] 3.6 [0.5] 3.7 [0.9] ns
Triglycerides [mmol/l] 2.5 [0.9] 1.6 [0.7] 0.03
HDL cholesterol [mmol/l] 1.04 [0.2] 1.36 [0.3] 0.03
Data are shown as a mean and one [standard deviation] NS = not significant; p > 0.05Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/7
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Glucose tolerance tests [GTT] and glycaemic control
Oral glucose tolerance tests [75 g anhydrous glucose
orally] were undertaken at 0800 hours with peripheral
venous blood samples taken at 0, 30, 60, 90 and 120 min-
utes from an indwelling ven ous cannula. Patients omit-
ted all oral hypoglycaemics on the morning of testing and
had been fasting for 15 hours. Patients remained seated
from time-15 minutes to 120 minutes.
Plasma soluble adhesion molecule concentrations
Plasma soluble intercellular adhesion molecule [s-ICAM-
1], soluble vascular cell adhesion molecule [s-VCAM-1]
and soluble E-selectin were measured during each glucose
tolerance test at 0 minutes and at 60, 90 and 120 minutes
after glucose loading. Concentrations of each soluble
adhesion molecule were quantified using commercially
available ELISA kits [R&D Systems plc, Abingdon, UK].
Plasma matrix metalloproteinase concentrations
Plasma MMP-3 and MMP-9 were measured at 0 and 90
minutes during the glucose tolerance test using BIOTRAK
human ELISA systems [Amersham Pharmacia Biotech;
Amersham, UK]. The MMP-3 assay detects total MMP-3
levels [pro, active, complexed] whereas the MMP-9 assay
detects pro and complexed forms of the enzyme.
Plasma low density lipoprotein oxidisability
Plasma low density lipoprotein [LDL] oxidisability was
measured at 0 and 90 minutes during each glucose toler-
ance test. The measurement of LDL susceptibility to oxida-
tion was determined by the delay [lag] in the production
of conjugated diene production at 234 nm by copper
stimulated oxidation based on the method described by
Kleinveld et al. [17].
Measurement of lipid fractions
Plasma lipid profiles were measured at time 0 and 90 min-
utes during each glucose tolerance test using commer-
cially available kits [Roche, Herts, UK] on an automated
biochemistry analyser [COBAS MIRA, Roche, Welwyn,
UK] with estimation of low density lipoprotein choles-
terol [18] from total cholesterol, HDL cholesterol and
triglycerides.
Measurement of glycaemic control
HbA1c was assessed using a commercially available kit
[Roche Diagnostic systems, Welwyn, Herts, UK] on an
automated biochemistry analyser [COBAS MIRA, Roche
Diagnostic systems, Welwyn, UK] with the normal range
quoted as 4.5 – 5.7%.
Statistical analysis
Data are shown as a mean and [one standard deviation]
and all variables were normally distributed other than
MMP-3 and MMP-9 concentrations [median and range].
Differences in individual variables during glucose toler-
ance tests were analysed by repeated measure one-way
ANOVA [significance expressed as an F value for differ-
ences across the 4 time points] with paired t tests where a
significant difference [p < 0.05] was found. Unpaired t
tests or Mann Whitney U tests were used as appropriate
for between group comparisons. Relationships between
variables were analysed by simple linear regression, or
stepped multiple regression analysis with entry at p < 0.1.
Data were analysed on Apple Macintosh Statview software
[1996].
Results
Clinical features and baseline data [Tables 1, 2]
Clinical and baseline data are shown in the Tables.
Groups did not differ in mean basal s ICAM-1 [p = 0.45]
or in s E selectin [p = 0.14], but sVCAM-1 was significantly
higher in the diabetes group compared to controls [p =
0.001].
Associations with baseline plasma soluble adhesion 
molecule concentrations
In the diabetes group, the only variables independently
directly associated with s ICAM-1 at baseline [0 mins]
were HbA1c [R2 = 0.29, F1,20 = 7.45; p = 0.01] and fasting
blood glucose [R2 = 0.16; F1,20 = 3.7; p = 0.06]. The only
variable independently associated with s E-selectin at
baseline [0 mins] was fasting blood glucose [R2 = 0.18;
F1,20= 4.3; p = 0.05]. However, s VCAM-1 concentrations
at baseline during were and unrelated solely to any meas-
ure of glycaemic control. In the control group, there were
no significant independent relationships between s
ICAM-1, s E-selectin, or s VCAM-1 concentrations and
fasting glucose or HbA1c measurments.
Plasma soluble adhesion molecules during GTT [Table 2]
In the diabetes group during GTT there was a significant
fall in mean plasma soluble ICAM-1 [F1,3 = 17.8; p <
0.0001], VCAM-1 [F1,3 = 14.1; p <0.0001] and E-selectin
concentrations F1,3 = 16.2; p < 0.0001]. The change was
significant by 60 minutes, and maximum decrements
were 9.7% [s ICAM-1], 12.9% [s VCAM-1] and 8.3% [s E-
selectin], reached at either 90 minutes [E-selectin] or 120
minutes [s ICAM-1, s VCAM-1]. In the control group there
were significant [p < 0.001] and equally prompt falls in
plasma s-ICAM-1 and s E-Selectin, but not in s VCAM-1
[Table 2] during GTT. At all time points during GTT, s
VCAM-1 concentrations were significantly higher in the
Type 2 diabetes group compared to controls [p < 0.05],
with no significant differences in s ICAM-1 or s E-selectin
concentrations between groups during GTT.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/7
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Associations with change in plasma adhesion molecule 
concentrations during GTT
In the diabetes group, the major determinant of the max-
imum change in adhesion molecule concentrations dur-
ing GTT was the maximum blood glucose increment
[mmol/l] for s ICAM-1 [F1,20 = 4.41; p = 0.048; R2 = 0.18]
and s E-selectin [F1,20 = 7.4; p = 0.013; R2 = 0.28], but not
s VCAM-c 1 [F1,20 = 0.09; p = 0.75; R2 = 0.04]. This rela-
tionship was stronger when percentage changes in plasma
s ICAM-1 [F1,20 = 4.9,; p = 0.028, R2 = 0. 23] and s E-selec-
tin [F1,20 = 7.8; p = 0.01; R2 = 0.29] were used. In the con-
trols, the maximum decrement in plasma s ICAM-1 and s-
selectin concentrations were unrelated to blood glucose
increment [p = 0.84 and 0.47 respectively]
Plasma MMP-3 and MMP-9 concentrations [Table 2]
Median plasma MMP-3 [p = 0.02] and MMP-9 [p = 0.04]
concentrations were significantly higher in the controls.
Median plasma MMP-3 and MMP-9 concentrations did
not change significantly during acute hyperglycaemia in
either group.
Associations with plasma MMP-3 & MMP-9 
concentrations
The only variable independently inversely related to
plasma MMP-3 levels at baseline was s-ICAM-1 [R2 =
0.30; F1,20 = 6.6; p = 0.03] in the diabetes group. The rela-
tionship between MMP-3 and s-ICAM-1 was independent
of all other variables, and there were no significant rela-
tionships between plasma MMP-3 levels and any measure
of glycaemic control, other adhesion molecules or plasma
LDL oxidisability. MMP-9 was undetectable in the diabe-
tes group. In the controls there was a strong direct inde-
pendent relationship only between plasma MMP-9 levels
and s ICAM-1 [R2 = 0.36; F = 9.73; p = 0.006].
LDL oxidisability [Table 2]
There was no significant difference between LDL lag times
at baseline and at 90 minutes in either diabetic or controls
groups, although lag times were significantly longer in the
control group [p = 0.01]
Discussion
The prompt highly significant fall in all plasma soluble
adhesion molecule concentrations following an oral glu-
cose load in Type 2 diabetes is a surprising observation as
Table 2: Changes in plasma soluble adhesion molecule, matrix metalloproteinase concentrations and LDL oxidisability during a glucose 
tolerance test in 21 patients with Type 2 diabetes and 20 controls.
Time [mins]
06 0 9 0 1 2 0 p
Type 2 diabetes
Blood glucose [mmol/l] 8.6 [2.7] 16.1 [3.8] * 17.8 [3.5] * 17.0 [3.6] * 0.0001
s ICAM-1 [ng/ml] 276 [85] 249 [76] * 249 [79] * 247 [78] * 0.0001
s VCAM-1 [ng/ml] 528 [222] 486 [216] * 472 [208] * 459 [194] * 0.0001
s E-Selectin [ng/ml] 82 [33] 76 [31]* 74 [32] * 75 [32] * 0.0001
LDL lag time [mins] 54. 8 [9.8] - 52.2 [9.3] ns
Plasma triglycerides [mmol/l] 2.5 [0.9] - 2.4 [0.7] ns
MMP-3 [ng/ml] 13.7 [0 – 71] - 18.0 [0 – 85] ns
MMP-9 [ng/ml] 0.0 [0 – 129] - 0.0 [0 – 75] ns
Controls
Time [mins] 06 0 9 0 1 2 0 p
Blood glucose [mmol/l] 4.6 [0.3] 7.0 [1.2] * 6.0 [1.1] * 5.4 [1.1] * 0.0001
s ICAM-1 [ng/ml] 280 [82] 219 [57] * 257 [70] * 230 [71] * 0.0001
s VCAM-1 [ng/ml] 321 [198] 349 [197] 321 [174] 338.7 [182] 0.23
s E-Selectin [ng/ml] 64 [24] 60 [21] 58 [22] ** 59 [21] 0.003
LDL lag time [mins] 71.3 [8.1] 74.3 [10.2] ns
Plasma triglycerides [mmol/l] 1.6 [0.7] 1.7 [0.8] ns
MMP-3 [ng/ml] 30.8 [12.8 – 39] 26.4 [4.3 – 37.4] ns
MMP-9 [ng/ml] 4.7 [1.2 – 41] 11.1 [2.5 – 41.9] * 0.03
Abbreviations as in text. All data shown as mean [SD] or as a median and range [MMP-3 and 9] and p values are for one way repeated measure 
ANOVA for each variable with * = p < 0.001, ** = p < 0.01 compared to time 0.Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/7
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in vitro, upregulation of membrane adhesion molecule
expression and message in endothelial and other cell lines
is associated with both high glucose concentrations and
increased intracellular oxidative stress [6-8], and other
smaller studies have described increased plasma concen-
trations of soluble adhesion molecules [particularly s
ICAM-1] in Type 2 diabetes and controls after a glucose
load [19-21]. In common with other studies in Type 2 dia-
betes, we also demonstrated a direct relationship between
measures of long term glycaemic control and plasma con-
centration of some soluble adhesion molecules
It is unlikely that the rapid fall in all plasma soluble adhe-
sion molecules concentrations represented decreased syn-
thesis and expression of all these proteins, as message for
the membrane bound forms of these adhesion molecules
takes several hours to regulate in vitro [22]. Also, the
mechanisms underlying these changes following a glu-
cose load must account for the rapid and highly signifi-
cant fall in all three measured plasma soluble adhesion
molecules and must be independent of acute substantial
hyperglycaemia as they also occurred in the control group,
where the changes were unrelated to glycaemic excur-
sions. Plasma soluble adhesion molecules are derived by
the proteolytic cleavage of the membrane bound adhe-
sion molecule at the point of membrane insertion [23].
The mechanisms controlling the shedding of these solu-
ble forms from the cell surface remain unclear, but in
some cell lines the membrane bound proteases that
release the soluble forms are zinc containing non-matrix
metalloproteinases [24]. Although there is no data on the
regulation of these membrane bound proteases by acute
glycaemic excursions, it is possible that any change within
minutes as occurred in the present study reflects reduced
proteolytic release of the adhesion molecule from the cell
surface, but this would imply that the release mechanisms
for all these adhesion molecules was similarly regulated
by acute hyperglycaemia, and of course the control group
[who did not experience acute hyperglycaemia] also
showed marked reductions in plasma soluble adhesion
molecule concentrations. We have shown recently in sep-
arate studies [25,26] that an oral glucose load leads to the
increased cell surface expression of peripheral blood
monocyte adhesion molecules CD11b [Mac-1] and LFA-1
in controls and in Type 2 diabetes, and increased expres-
sion of the monocyte LDL scavenger receptor CD36 in
controls without diabetes. Leukocyte CD11b and LFA-1
are central to leukocyte-endothelium adhesion, and we
also recorded a similar significant fall in plasma soluble
adhesion molecules in parallel with increased monocyte
expression of these adhesion molecules [25]. One possi-
ble interpretation of the data in the present study is that
increased leukocyte adhesion molecule expression follow-
ing a glucose load in Type 2 diabetes and controls leads to
enhanced leukocyte – endothelial interactions and a tran-
sient decrease in endothelial and leukocyte shedding of
the soluble forms into the plasma.
Another possibility is that the rapid, consistent fall in a
plasma soluble adhesion molecules in both groups after a
glucose load reflects increased clearance of these plasma
proteins. An oral or intravenous glucose load increases
splanchnic and hepatic blood flow by up to 40% within
minutes in man and animal models and in both diabetes
and control subjects [27,28] and is in part a function of
changes in portal vein osmolarity which might increase
hepatic clearance of these proteins. Finally, acute hyperin-
sulinaemia is unlikely to have produced this effect as an
acute 30-fold increase in plasma insulin concentrations
has no effect on plasma soluble adhesion molecule con-
centrations [29,30] Our findings differ from those of Ceri-
ello et al [19], Marfella et al [20] and Nappo et al [21] who
performed a single oral [19] or intravenous [20] glucose
tolerance test in 9 [19] and 10 [20] patients respectively
with Type 2 diabetes and reported a significant increase in
plasma s ICAM-1 concentrations at 60 – 90 minutes, or
increased plasma soluble adhesion molecules concentra-
tions in 20 Type 2 patients following a carbohydrate meal
[21]. The patients in these studies were similar in baseline
glycaemic control, glycaemic excursions and basal s
ICAM-1 levels to the present study, the major difference
being the larger sample size in the present study.
There was no significant change in LDL oxidisability dur-
ing hyperglycaemia although increased oxidative stress
and antioxidant consumption post-prandially has been
suggested as a possible mechanism for increased lipopro-
tein oxidisability in diabetes [15]. Others have described
increased LDL oxidisability in Type 2 diabetes after a fat
containing meal, using a methodology similar to ours
[16]. A meal rich in oxidised lipids may lead to an acute
rise in lipoprotein conjugated dienes in Type 2 diabetes
[31] and this could be a confounding mechanism for
apparent post-prandial changes in LDL oxidisability after
a fat meal, which do not occur when a glucose load is
used. The present study had 89% power at the 5% level to
detect one standard deviation difference in LDL lag times
between time points in the diabetes group. This difference
[9.8 mins] is biologically relevant as it is similar to or less
than the difference seen between groups with or without
atherosclerosis [32]
Despite the interest in MMP as mediators of the develop-
ment of cardiovascular disease there is surprisingly little
data on plasma MMP levels in Type 2 diabetes. Other
groups have been able to detect plasma MMP-9 in Type 1
and 2 diabetes [33,34], and we have shown that periph-
eral venous monocytes derived from patients with Type 2
diabetes do not differ in the expression of MMP-3, MMP-
9 or TIMP-1 compared to controls [35], although fibrob-Cardiovascular Diabetology 2004, 3 http://www.cardiab.com/content/3/1/7
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lasts derived from the healthy skin of diabetic patients
show increased expression of MMP-2 and MMP-3 com-
pared to controls [36]. The significant inverse relationship
between s ICAM-1 and plasma MMP-3 levels in the diabe-
tes group alone and the strong direct relationship between
s ICAM-1 and MMP-9 in the controls is intriguing. Others
have shown that endothelial cell expression of MMP-9 is
promoted by LFA-1 /ICAM-1 mediated cell adhesion to
the endothelium [37], and that ICAM-1 release from some
cell lines is mediated by MMP-9 [38], and which may have
been detected in this study.
Although the changes in plasma soluble adhesion mole-
cule concentrations in Type 2 diabetes and controls fol-
lowing an oral glucose load were highly significant, and
have been reproduced in our other studies [25], this study
has limitations. Firstly, as the mechanisms underlying
these observations are unclear, it would be interesting to
examine the effects of an oral fat load, intravenous glucose
load or calorie free oral load on these varaiables. Sec-
ondly, other key adhesion molecules such as p-selectin
were not studied. P-selectin storage and release from intra-
cellular compartments [39,40] would make it an attractive
candidate for further study as it may be more sensitive to
physiological changes following a glucose load. Finally it
would have been informative to study leukocyte counts,
as polymorphonuclear leukocytes are a rich source of pro-
teases and potentially of shed s ICAM-1, and to examine
MMP levels with gelatin or casein zymography rather than
ELISA assays to better distinguish active from inactive
forms of the enzymes.
In summary we have shown that a glucose load in Type 2
diabetes and controls leads to a rapid decrement in
plasma soluble adhesion molecule concentrations and
this may be a function of impaired shedding of these pro-
teins or increased hepatic clearance. These findings in vivo
are in contrast to that those expected from in vitro data on
glucose and adhesion molecule expression. Glycaemic
excursions following a glucose load do not influence
plasma MMP concentrations or LDL oxidisability in Type
2 diabetes.
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